Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
Jun 22, 2020AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) VIRTUAL ANNUAL MEETING II
May 29, 2020ASCO20 VIRTUAL SCIENTIFIC PROGRAM
May 26 - May 27, 2020SACHS ASSOCIATES 6TH ANNUAL DIGITAL IMMUNO-ONCOLOGY INNOVATION FORUM